This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gana-Weisz, M. Articles by Kloog, Y. Search for Related Content PubMed PubMed Citation Articles by Gana-Weisz, M. Articles by Kloog, Y.

The Ras Inhibitor S-trans,trans-Farnesylthiosalicylic Acid Chemosensitizes Human Tumor Cells Without Causing Resistance¹

Department of Neurobiochemistry, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, 69978 Tel Aviv, Israel [M. G-W., G. E., R. H., Y. K.], and Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology and Department of Dermatology, Division of General Dermatology, University of Vienna, Vienna, A-1090 Austria [J. H-W., B. J.]

Ras transformation requires Ras membrane anchorage, which is promoted by a farnesylcysteine carboxymethyl ester and by additional sequences specific to each Ras isoform. We showed previously that S-trans,trans-farnesylthiosalicylic acid (FTS) disrupts Ras membrane anchorage and that this disturbance contributes to inhibition of cell transformation and tumor growth. Most tumor cells develop resistance to anticancer agents. Here we examined whether tumor cells develop resistance to FTS and evaluated the therapeutic potential of FTS combined with cytotoxic drugs, because oncogenic Ras promotes antiapoptotic signals in tumors of epithelial origin. We showed that Panc-1 pancreatic cancer cells, SW480 colon cancer cells, and H-ras (EJ)-transformed Rat-1 fibroblasts exposed to FTS for prolonged periods (>6 months) do not escape FTS-induced growth inhibition and do not develop drug resistance. These cells continued to express reduced amounts of Ras, exhibit a reversed phenotype, and show an altered response to the cytotoxic drugs doxorubicin and gemcitabine. FTS-treated Panc-1 or SW480 cells acquired sensitivity to the cytotoxic drugs, whereas FTS-treated EJ cells lost sensitivity to doxorubicin, reflecting the opposite effects of oncogenic Ras on the survival of epithelial cells and fibroblasts. Treatment with FTS led to a marked increase in sensitivity to gemcitabine of the formerly resistant SW480 cells and a 100-fold increase in sensitivity to gemcitabine of Panc-1 cells. Such treatment in mice with preexisting Panc-1 tumors provided a synergistic effect of FTS and gemcitabine, leading to enhanced inhibition of tumor growth and a 65% increase in survival rate.

This article has been cited by other articles:

				L. Goldberg, A. Ocherashvilli, D. Daniels, D. Last, Z. R. Cohen, G. Tamar, Y. Kloog, and Y. Mardor Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats Mol. Cancer Ther., November 1, 2008; 7(11): 3609 - 3616. [Abstract] [Full Text] [PDF]

				A. Zundelevich, G. Elad-Sfadia, R. Haklai, and Y. Kloog Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid) Mol. Cancer Ther., June 1, 2007; 6(6): 1765 - 1773. [Abstract] [Full Text] [PDF]

				B. Barkan, S. Starinsky, E. Friedman, R. Stein, and Y. Kloog The Ras Inhibitor Farnesylthiosalicylic Acid as a Potential Therapy for Neurofibromatosis Type 1. Clin. Cancer Res., September 15, 2006; 12(18): 5533 - 5542. [Abstract] [Full Text] [PDF]

				Q. Zhang, J. Li, M. Deavers, J. L. Abbruzzese, and L. Ho The Subcellular Localization of Syntaxin 17 Varies Among Different Cell Types and Is Altered in Some Malignant Cells J. Histochem. Cytochem., November 1, 2005; 53(11): 1371 - 1382. [Abstract] [Full Text] [PDF]

				I.-A. Kim, S.-S. Bae, A. Fernandes, J. Wu, R. J. Muschel, W. G. McKenna, M. J. Birnbaum, and E. J. Bernhard Selective Inhibition of Ras, Phosphoinositide 3 Kinase, and Akt Isoforms Increases the Radiosensitivity of Human Carcinoma Cell Lines Cancer Res., September 1, 2005; 65(17): 7902 - 7910. [Abstract] [Full Text] [PDF]

				R. Shalom-Feuerstein, T. Cooks, A. Raz, and Y. Kloog Galectin-3 Regulates a Molecular Switch from N-Ras to K-Ras Usage in Human Breast Carcinoma Cells Cancer Res., August 15, 2005; 65(16): 7292 - 7300. [Abstract] [Full Text] [PDF]

				M. D. Morgan, L. Harper, X. Lu, G. Nash, J. Williams, and C. O. S. Savage Can neutrophils be manipulated in vivo? Rheumatology, May 1, 2005; 44(5): 597 - 601. [Full Text] [PDF]

				H. Rodrigues Goulart, E. A. Kimura, V. J. Peres, A. S. Couto, F. A. Aquino Duarte, and A. M. Katzin Terpenes Arrest Parasite Development and Inhibit Biosynthesis of Isoprenoids in Plasmodium falciparum Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2502 - 2509. [Abstract] [Full Text] [PDF]

				H. Mo and C. E. Elson Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585. [Abstract] [Full Text] [PDF]

				H. Bernstein, C. M. Payne, K. Kunke, C. L. Crowley-Weber, C. N. Waltmire, K. Dvorakova, H. Holubec, C. Bernstein, R. R. Vaillancourt, D. A. Raynes, et al. A proteomic study of resistance to deoxycholate-induced apoptosis Carcinogenesis, May 1, 2004; 25(5): 681 - 692. [Abstract] [Full Text] [PDF]

				H. Niv, O. Gutman, Y. Kloog, and Y. I. Henis Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells J. Cell Biol., May 28, 2002; 157(5): 865 - 872. [Abstract] [Full Text] [PDF]